TAF/FTC/DTG
(TENOFOVIR ALAFENAMIDE/EMTRICITABINE/DOLUTEGRAVIR)



- Due to lack of clinical data, TAF is not on the WHO Guidelines as of now. However, generics have already started developing TAF combinations
- 10 MPP licensees are developing TAF/FTC/DTG, of which:
  - **Mylan** has filed with USFDA and received approval
  - Two additional filings are planned by end of 2018
- We anticipate development by additional licensees to accelerate once there is an update on WHO's position about use of TAF-containing formulations

TAF/FTC
(TENOFOVIR ALAFENAMIDE/EMTRICITABINE)



- Five MPP licensees are developing TAF/FTC, of which:
  - One company has filed with USFDA
  - One company is planning to file with USFDA in Q4-18
  - An additional three companies are expected to file in 2019
- We anticipate additional licensees to start development once greater clarity is obtained through WHO on the use of TAF and its combinations

Note: Gilead has direct licences with additional manufacturers, details of which are not captured here